- In December 2021, Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry, for USD 17.4 billion
- In November 2020, AMSBIO announced development services for rabbit and mouse recombinant monoclonal antibodies. The development of recombinant monoclonal antibodies is based on the DimAb development platform, which is different from conventional hybridoma fusion technologies. It has ability to isolate IgG genes from B cells of immunized animals. These antibodies assist in the development and commercialization of drugs in the market. In October 2019, the FDA approved first rabbit monoclonal antibody-derived drug—Beovu. Beovu is intended to treat wet age-related macular degeneration (AMD)
- In March 2020, Absolute Antibody Ltd announced the launch of high-throughput recombinant antibody production service for its FleXpress. The company offers its customers with services for facilitating the rapid expression of many antibodies, up to a volume of 80 ml scale, as well as for propelling the production capacity to meet rising demands for recombinant antibody technology
